Advanced Medical Solutions Group Regulatory News (AMS)

5 July 2018

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Trading Update

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces a trading update covering the six-month period 1 January to 30 June 2018.

AMS continues to make good progress across the Group and can confirm that trading is in line with the Board's expectations. 

Chris Meredith, Chief Executive Officer of AMS, commented: "The Board is pleased with the ongoing performance of the business and we remain on track for the full year. We continue to be focused on our strategic objectives to grow organically and through acquisition whilst delivering innovation from our Research and Development pipeline."

The Group expects to publish its Interim Results for the period to 30 June 2018 on 12 September 2018.

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.